24 - 27 January 2022

Dubai World Trade Centre

5 January - 28 February

Treating Aortic Valve Disease with AV Neo in non-elderly patients - Re-establishing natural blood flow

 

JOMDD

 

Wednesday 26th January | 16:00

Transformation Zone | S2.D70

Product description


AVNeo (Aortic Valve Neocuspidization)


AVNeo (Aortic Valve Neocuspidization) is a standardized revolutionary procedural technique used to reconstruct the aortic heart valve using the patient's own pericardial tissue.​

Partnering with JOMDD and the Saudi Arabian Ministry of Health, Abdul Latif Jameel Health is introducing this pioneering life saving procedure into Saudi Arabia. Latest data showed the 10-year survival rate was 85.9% for AVNeo compared to less than 80% for alternative procedures.​

The AV Neo solution is represented in the Middle East and Africa by Abdul Latif Jameel Health.

 

Company bio


Abdul Latif Jameel Health introduces: AV Neo from JOMDD


Partnering with JOMDD and the Saudi Arabian Ministry of Health, Abdul Latif Jameel Health is introducing this pioneering life saving procedure into Saudi Arabia. Latest data showed the 10-year survival rate was 85.9% for AVNeo compared to less than 80% for alternative procedures.​ The AV Neo solution is represented in the Middle East and Africa by Abdul Latif Jameel Health.

Presenters


Dr. Akram Bouchenaki
CEO Abdul Latif Jameel Health

Akram Bouchenaki is Chief Executive Officer of Abdul Latif Jameel Health, Abdul Latif Jameel’s health care business, focusing on accelerating access to modern medical care while addressing unmet medical needs in developing markets around the World. Abdul Latif Jameel Health is part of Abdul Latif Jameel, a collective of independent international, family-owned and diversified businesses, founded in 1945 by the late Abdul Latif Jameel.

Dr. Bouchenaki joins Abdul Latif Jameel Health after 25 years of operational and strategic roles in the pharmaceutical and healthcare sectors, including global leadership roles in ‘big-pharma’ corporates as well as in top California-based biotech, where he was an executive director for Africa covering the largest markets on the continent.

Akram has extensive knowledge and experience of both generics and branded medicines in established as well as key emerging markets across the world. These include Africa’s most significant markets, Brazil, and Mexico, having co-founded a fast-growing start-up to commercialize medicines in Latin America.

Akram holds a Doctorate in Pharmacy from Université de Paris V, France. He has lived and worked in 9 different countries across 5 continents. He speaks French, Spanish, Arabic, Portuguese and English.

Dr. Takahiro UCHIDA
CEO, Japanese Organization for Medical Device Development (JOMDD)

Takahiro is a doctor of cardiovascular medicine and the only Japanese medical device examiner of US FDA. He established JOMDD in 2012 to build an open innovation platform to provide commercialize healthcare innovations, He also believes that the availability of health care is an important societal pillar in each country, and it is in everyone’s best interest that people worldwide have access to the best possible healthcare.

Mr. Damon Lawson
Director, Japanese Organization for Medical Device Development (JOMDD)

Damon Lawson is an "Advisor - Medical Design" at Japanese Organization for Medical Device Development, Inc. (JOMDD), His expertise lies in developing and executing marketing strategies and relationship building with KOLs.